Publication | Open Access

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

OncologyHepatologyClinical TrialsRamucirumab Versus PlaceboPharmacotherapyLiver CancerCancer TreatmentMedicineRadiation OncologyHepatocellular CarcinomaPhase 3Advanced Hepatocellular CarcinomaHealth Sciences